Literature DB >> 19229559

SCA8 repeat expansion: large CTA/CTG repeat alleles in neurological disorders and functional implications.

Yih-Ru Wu1, I-Cheng Chen, Bing-Wen Soong, Shih-Huan Kao, Ghin-Chueh Lee, Shu-Yi Huang, Hon-Chung Fung, Guey-Jen Lee-Chen, Chiung-Mei Chen.   

Abstract

Spinocerebellar ataxia type 8 (SCA8) involves bidirectional expression of CUG (ATXN8OS) and CAG (ATXN8) expansion transcripts. The pathogenesis of SCA8 is complex and the spectrum of clinical presentations is broad. In the present study, we assessed the SCA8 repeat size ranges in Taiwanese Parkinson's disease, Alzheimer's disease and atypical parkinsonism and investigated the genetic variation modulating ATXN8 expression. Thirteen large SCA8 alleles and a novel ATXN8 -62 G/A promoter SNP were found. There is a significant difference in the proportion of the individuals carrying SCA8 larger alleles in atypical parkinsonism (P = 0.044) as compared to that in the control subjects. In lymphoblastoid cells carrying SCA8 large alleles, treatment of MG-132 or staurosporine significantly increases the cell death or caspase 3 activity. Although expressed at low steady-state, ATXN8 expression level is significantly higher (P = 0.012) in cells with SCA8 large alleles than that of the control cells. The ATXN8 transcriptional activity was significantly higher in the luciferase reporter construct containing the -62G allele than that containing the -62A allele in both neuroblastoma and embryonic kidney cells. Therefore, our preliminary results suggest that ATXN8 gene -62 G/A polymorphism may be functional in modulating ATXN8 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229559     DOI: 10.1007/s00439-009-0641-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  Are (CTG)n expansions at the SCA8 locus rare polymorphisms?

Authors:  G Stevanin; A Herman; A Dürr; C Jodice; M Frontali; Y Agid; A Brice
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8.

Authors:  Melinda L Moseley; Tao Zu; Yoshio Ikeda; Wangcai Gao; Anne K Mosemiller; Randy S Daughters; Gang Chen; Marcy R Weatherspoon; H Brent Clark; Timothy J Ebner; John W Day; Laura P W Ranum
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

3.  The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1).

Authors:  J P Nemes; K A Benzow; M L Moseley; L P Ranum; M D Koob
Journal:  Hum Mol Genet       Date:  2000-06-12       Impact factor: 6.150

4.  Molecular and clinical analyses of spinocerebellar ataxia type 8 in Japan.

Authors:  Y Ikeda; M Shizuka; M Watanabe; K Okamoto; M Shoji
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

5.  HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.

Authors:  Simone G Sala; Ursula Muñoz; Fernando Bartolomé; Félix Bermejo; Angeles Martín-Requero
Journal:  J Pharmacol Exp Ther       Date:  2007-10-10       Impact factor: 4.030

6.  White matter hyperintense lesions in genetically proven spinocerebellar ataxia 8.

Authors:  Neeraj Kumar; Gary M Miller
Journal:  Clin Neurol Neurosurg       Date:  2007-10-24       Impact factor: 1.876

7.  Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes.

Authors:  Yoshio Ikeda; Randy S Daughters; Laura P W Ranum
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease.

Authors:  Y R Wu; H Y Lin; C M Chen; K Gwinn-Hardy; L S Ro; Y C Wang; S H Li; J C Hwang; K Fang; H M Hsieh-Li; M L Li; L C Tung; M T Su; K T Lu; G J Lee-Chen
Journal:  Clin Genet       Date:  2004-03       Impact factor: 4.438

9.  Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia.

Authors:  Yoshio Ikeda; Joline C Dalton; Melinda L Moseley; Kathy L Gardner; Thomas D Bird; Tetsuo Ashizawa; William K Seltzer; Massimo Pandolfo; Aubrey Milunsky; Nicholas T Potter; Mikio Shoji; John B Vincent; John W Day; Laura P W Ranum
Journal:  Am J Hum Genet       Date:  2004-05-19       Impact factor: 11.025

10.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

View more
  5 in total

1.  Genetic and clinical analyses of spinocerebellar ataxia type 8 in mainland China.

Authors:  Yao Zhou; Yanchun Yuan; Zhen Liu; Sheng Zeng; Zhao Chen; Lu Shen; Hong Jiang; Kun Xia; Beisha Tang; Junling Wang
Journal:  J Neurol       Date:  2019-08-30       Impact factor: 4.849

2.  Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli.

Authors:  Han-Joon Kim; Beom S Jeon; Min-Yung Yoon; Sung-Sup Park; Kwang-Woo Lee
Journal:  J Mol Neurosci       Date:  2012-03-06       Impact factor: 3.444

3.  PSP-Phenotype in SCA8: Case Report and Systemic Review.

Authors:  Makoto Samukawa; Makito Hirano; Kazumasa Saigoh; Shigeru Kawai; Yukihiro Hamada; Daisuke Takahashi; Yusaku Nakamura; Susumu Kusunoki
Journal:  Cerebellum       Date:  2019-02       Impact factor: 3.847

Review 4.  Parkinsonism in spinocerebellar ataxia.

Authors:  Hyeyoung Park; Han-Joon Kim; Beom S Jeon
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

5.  Non-Ataxic Phenotypes of SCA8 Mimicking Amyotrophic Lateral Sclerosis and Parkinson Disease.

Authors:  Ji Sun Kim; Tae Ok Son; Jinyoung Youn; Chang-Seok Ki; Jin Whan Cho
Journal:  J Clin Neurol       Date:  2013-10-31       Impact factor: 3.077

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.